EP4720057A2 - Composés et compositions pouvant être utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations - Google Patents

Composés et compositions pouvant être utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations

Info

Publication number
EP4720057A2
EP4720057A2 EP24736895.4A EP24736895A EP4720057A2 EP 4720057 A2 EP4720057 A2 EP 4720057A2 EP 24736895 A EP24736895 A EP 24736895A EP 4720057 A2 EP4720057 A2 EP 4720057A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
carbocyclyl
alkoxy
alkylamino
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24736895.4A
Other languages
German (de)
English (en)
Inventor
Xuqing Zhang
Jeremy ROACH
Qiaolin Deng
E. Scott Priestley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopia Therapeutics Inc D/b/a Sk Life Science Labs
Original Assignee
Oncopia Therapeutics Inc D/b/a Sk Life Science Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopia Therapeutics Inc D/b/a Sk Life Science Labs filed Critical Oncopia Therapeutics Inc D/b/a Sk Life Science Labs
Publication of EP4720057A2 publication Critical patent/EP4720057A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des composés de formule I et leurs sels, solvates ou stéréoisomères pharmaceutiquement acceptables, ainsi que leurs utilisations (par exemple pour dégrader certaines protéines telles que des protéines CBP/p300).<i />
EP24736895.4A 2023-05-31 2024-05-31 Composés et compositions pouvant être utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations Pending EP4720057A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363505201P 2023-05-31 2023-05-31
US202363519002P 2023-08-11 2023-08-11
PCT/US2024/032041 WO2024249888A2 (fr) 2023-05-31 2024-05-31 Composés et compositions pouvant être utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4720057A2 true EP4720057A2 (fr) 2026-04-08

Family

ID=91699989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24736895.4A Pending EP4720057A2 (fr) 2023-05-31 2024-05-31 Composés et compositions pouvant être utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4720057A2 (fr)
JP (1) JP2026521988A (fr)
KR (1) KR20260032474A (fr)
CN (1) CN121605104A (fr)
AU (1) AU2024280630A1 (fr)
TW (1) TW202502335A (fr)
WO (1) WO2024249888A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4780815A1 (fr) * 2023-09-20 2026-07-29 Aurigene Oncology Limited Composés hétérocycliques utilisés en tant qu'agents de dégradation sélectifs de cbp
WO2025172917A1 (fr) * 2024-02-17 2025-08-21 Aurigene Oncology Limited Composés hétérocycliques utilisés en tant qu'agents de dégradation de p300

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
US20240150360A1 (en) * 2021-03-04 2024-05-09 The Regents Of The University Of Michigan Small Molecule Degraders of CBP/p300 Proteins
WO2024130095A1 (fr) * 2022-12-16 2024-06-20 Regents Of The University Of Michigan Composés et compositions utilisés en tant qu'agents de dégradation de cbp/p300 et leurs utilisations

Also Published As

Publication number Publication date
TW202502335A (zh) 2025-01-16
WO2024249888A3 (fr) 2025-02-13
JP2026521988A (ja) 2026-07-03
KR20260032474A (ko) 2026-03-09
CN121605104A (zh) 2026-03-03
WO2024249888A2 (fr) 2024-12-05
AU2024280630A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
US10640503B2 (en) Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US10556908B2 (en) Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
AU2016243939B2 (en) Heterocyclic compounds as LSD1 inhibitors
US11919902B2 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2024130095A1 (fr) Composés et compositions utilisés en tant qu&#39;agents de dégradation de cbp/p300 et leurs utilisations
AU2018224488A1 (en) Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
NZ562468A (en) Purine and imidazopyridine derivatives for immunosuppression
WO2024249888A2 (fr) Composés et compositions pouvant être utilisés en tant qu&#39;agents de dégradation de cbp/p300 et leurs utilisations
KR20160055170A (ko) 바이아릴 아세트아미드 화합물 및 이의 사용 방법
RS67253B1 (sr) Azahinolini kao inhibitori cd38
KR20230157432A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
TW201920157A (zh) 作為泛素–特異性蛋白酶抑制劑之甲醯胺
AU2024333590A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
US20220306640A1 (en) Hydantoin derivative
AU2015263013A1 (en) Fused triazole derivatives as phosphodiesterase 10A inhibitors
WO2024255765A1 (fr) Nouveaux composés, compositions les comprenant et leurs utilisations
CN108699065A (zh) 作为激酶抑制剂的三环类化合物和组合物
WO2014029732A1 (fr) Pyrrolo[2,3-b]pyrazines comme inhibiteurs de syk
AU2023375677A1 (en) COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
AU2020403681A1 (en) Compound and composition as pdgf receptor kinase inhibitor
WO2025049976A1 (fr) Composés et compositions en tant qu&#39;agents de dégradation de cbp/p300 et leurs utilisations
EP3597642A1 (fr) Dérivés pharmaceutiques de noyau hétérobicyclique 6,5
WO2025106482A1 (fr) Composés et compositions utilisés en tant qu&#39;agents de dégradation de smarca2/4 et leurs utilisations
TW202525805A (zh) 雙環類化合物及其製備方法和應用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR